Archive: 17/12/2016
Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong
Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapore.
Dec 17, 2016
Ribociclib improves progression-free survival in Asian women with advanced breast cancer
Ribociclib significantly improves progression-free survival in Asian women with advanced breast cancer, according to a sub-analysis of the MONALEESA-2 trial presented at the ESMO Asia 2016 Congress in Singapore.
Dec 17, 2016
Anxiety and depression a major issue for cancer survivors
Cancer has a major impact on mental and physical wellbeing, researchers report at the ESMO Asia 2016 Congress in Singapore.
Dec 17, 2016
Cancer costs leaving patients in debt
Cancer patients are ending up in debt because they have to cover the costs of treatment as well as other care related expenses, researchers report at the ESMO Asia 2016 Congress in Singapore.
Dec 17, 2016
Routine blood test predicts how long cancer patients will survive
A routine blood test can predict how long cancer patients in palliative care will survive, researchers report at the ESMO Asia 2016 Congress in Singapore.
Dec 17, 2016